Capricor Therapeutics (NASDAQ:CAPR) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a research report report published on Wednesday, Benzinga reports. HC Wainwright currently has a $40.00 price objective on the biotechnology company’s stock.

Several other research analysts also recently issued reports on the stock. Oppenheimer reiterated an outperform rating and set a $15.00 price target on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Cantor Fitzgerald reiterated an overweight rating and set a $8.00 target price on shares of Capricor Therapeutics in a research report on Friday, September 20th. Finally, Maxim Group increased their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a buy rating in a research note on Wednesday, September 25th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Capricor Therapeutics currently has an average rating of Moderate Buy and a consensus target price of $22.60.

Capricor Therapeutics Trading Up 3.7 %

Shares of Capricor Therapeutics stock opened at $17.77 on Wednesday. The stock has a market capitalization of $568.27 million, a price-to-earnings ratio of -20.43 and a beta of 4.01. The firm’s 50-day moving average price is $7.44 and its two-hundred day moving average price is $6.07. Capricor Therapeutics has a 1-year low of $2.68 and a 1-year high of $21.98.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). The business had revenue of $3.97 million for the quarter, compared to analyst estimates of $4.51 million. Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. As a group, equities research analysts predict that Capricor Therapeutics will post -1.13 EPS for the current year.

Insider Buying and Selling at Capricor Therapeutics

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the stock in a transaction dated Friday, September 20th. The stock was bought at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the transaction, the insider now directly owns 7,090,351 shares in the company, valued at $38,004,281.36. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 12.00% of the company’s stock.

Institutional Investors Weigh In On Capricor Therapeutics

Institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets acquired a new position in Capricor Therapeutics in the first quarter valued at about $40,000. Main Street Financial Solutions LLC increased its stake in shares of Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after acquiring an additional 7,500 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Capricor Therapeutics in the 3rd quarter valued at approximately $133,000. Rhumbline Advisers bought a new position in Capricor Therapeutics during the 2nd quarter worth approximately $147,000. Finally, Bank of New York Mellon Corp boosted its stake in Capricor Therapeutics by 12.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after acquiring an additional 9,040 shares during the last quarter. 21.68% of the stock is owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.